Important note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date. TAGline - Volume 11 Issue 9 - September 2004
ACTG HIV Research Agenda Committee (RAC) membership and ties to industry:
Joseph J. Eron, Jr., M.D.
Consulting arrangements with GlaxoSmithKline, Merck, Triangle, Trimeris. Research grants: GlaxoSmithKline, Merck, Abbott, Agouron, Triangle, and Trimeris.
Roy (Trip) Gulick, M.D., M.P.H.
Consultancy fees from two pharma companies (not identified) of less than $20,000 a year; and research funding from two pharma companies (not identified) of less than $20,000 a year. # Consultancy fees from: Bristol-Myers Squibb, GlaxoSmithKline, Triangle, Trimeris; Speakers bureau services for: Abbott, Agouron, GSK, Pharmacia-Upjohn (now part of Pfizer), Triangle.
Ann C. Collier, M.D.
Consulting arrangements with Merck. Research grants: Agouron, Merck, Hoffmann-La Roche, Glaxo-Wellcome, and Anor Med.
Eric S Daar, M.D.
Consulting arrangements with Abbott, Boehringer Ingelheim, GlaxoSmithKline, Gilead, Serono, ViroLogics. Speaking honoraria from: Abbott, Boehringer Ingelheim, GlaxoSmithKline, Gilead, Roche, Merck, Serono, ViroLogics, Ortho. Research grants: Abbott, Bayer, GlaxoSmithKline, Gilead, Roche, Merck, ViroLogics, Serono. †
Margaret A. Fischl, M.D.
Consultancy arrangements with and grant support (not broken out in disclosure) from: Abbott, Agouron, Bristol-Myers Squibb, DuPont, GlaxoSmithKline, Triangle.§
Richard Haubrich, M.D.
Speakers bureau member for: Agouron, GlaxoSmithKline, Trimeris, ViroLogics; Grant support from same.†
Victoria A. Johnson, M.D.
(Nothing found)
John W. Mellors, M.D.
Consultancy fees from: Agouron, Bristol-Myers Squibb, DuPont (now part of BMS), GlaxoSmithKline, Gilead, Merck, Novirio, Pharmasett, Triangle, Virco, Visible Genetics††; Grant support: BMS, Chiron, DuPont (now part of Bristol), GlaxoSmithKline, Merck.
Andrew R. Zolopa, M.D.
Consulting arrangements with Abbott, Bristol-Myers Squibb, and Merck. Research grants: Abbott, Bristol-Myers Squibb, and DuPont.†
Angell: "Increasingly, panel members and med 'educators' are required to disclose their financial ties. And that disclosure is supposed to make it acceptable that they have them." TTATDC, p140
040910
TAG041109-04C
Copyright © 2004 - Treatment Action Group. TAGLine is published monthly by the Treatment Action Group (TAG), a 501(c)(3) non-profit treatment advocacy organization in New York City. email: , 611 Broadway, Ste. 612 · New York, NY 10012, phone: (212) 253-7922 · fax: (212) 253-7923.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, charitable and educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, the National Library of Medicine, Bridgestone Firestone Trust Fund, and donations from users like you. Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .